Form 6-K ASTRAZENECA PLC For: Feb 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
AstraZeneca (AZN) Misses Q3 EPS by 9c
February 5, 2015 8:49 AM ESTAstraZeneca (NYSE: AZN) reported Q3 EPS of $0.76, $0.09 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $6.68 billion versus the consensus estimate of $6.68 billion.
Pascal Soriot, Chief Executive Officer, commenting on the results, said:
2014 was a remarkable year for AstraZeneca. We achieved a record six product... More
